Technology Foundation STW grant for cartilage repair
‘There’s no cure for osteoarthritis’, is what Wikipedia and all available textbooks say. The world famous anatomist William Hunter already said it in 1743, writing about joint diseases.
According to the consortium ‘William Hunter revisited’, led by Prof. Karperien (University of Twente), it is now time to revise this. The group of scientists and companies aims at stopping osteoarthritis and joint wear. Based on recent developments they expect it is even possible to regrow cartilage.
The ambition of the consortium is to develop a method for treating cartilage defects that is ready for clinical use. Apart from that, the partners will develop techniques for early diagnostics and monitoring of the joint’s health status.
Tim Welting and Pieter Emans from the Department of Orthopaedic Surgery will participate in two work packages (WP). In WP4 cell model / bioassays will be developed to identify catabolic and anabolic properties of joints. In this WP two PhD candidates will be appointed; one at the Department of Orthopaedic Surgery, MUMC+ and one at Radboudumc.
In WP6 tools to collect synovial fluid from patients will be developed. In this WP one PhD candidate will be appointed as well as a 0.5FTE postdoc.
Technology Foundation STW realises the transfer of knowledge between the technical sciences and users by funding excellent technical scientific research and by bringing researchers and users together in each project.
Also read
-
Doubts about vaccination continue to be a significant challenge for global public health. The World Health Organisation (WHO) has listed vaccine hesitancy as one of the top ten threats to global health.
But what exactly is vaccine hesitancy and how does it impact our society? How can we address it, particularly in healthcare? PhD candidate Veja Widdershoven conducted research into these questions and proposed ways to approach vaccine hesitancy.
-
What role do nerve cells play in colorectal cancer? In this Science Story, Veerle Melotte explains her research.
-
With a new decision model from researchers at GROW within MUMC+, these prospective parents know more quickly if they qualify for embryo selection.
